Treating diabetes with genetically modified beta cells
AssigneeWallkill BioPharma, Inc.
InventorsDavid Kiewlich, Gerald F. Swiss
Life of this patent
Estimating the term…
Abstract
Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
Claims20
A method for producing insulin in response to a hyperglycemic environment comprising contacting said environment with a population of human transgenic beta cells, wherein each transgenic human beta cell expresses or overexpresses a human fugetactic agent in an amount sufficient to render said beta cell resistant to human immune cells, wherein said beta cell is capable of expressing insulin and incapable of cell division.
A method for producing insulin in response to a hyperglycemic environment comprising contacting said environment with a population of human transgenic beta cells, wherein each transgenic human beta cell comprises a vector comprising a nucleic acid sequence encoding human CXCL12, wherein said beta cell is resistant to human immune cells.
A method for producing insulin in response to a hyperglycemic environment comprising contacting said environment with a population of human transgenic beta cells, wherein each transgenic human beta cell comprises a transgenic regulatory region upstream of an endogenous CXCL12 coding region wherein said beta cell is resistant to human immune cells.
A method for treating diabetes in a patient in need thereof, the method comprising contacting said environment with a population of human transgenic beta cells, wherein each transgenic human beta cell expresses or overexpresses a human fugetactic agent in an amount sufficient to render said beta cell resistant to human immune cells, wherein said beta cell is capable of expressing insulin and incapable of cell division.
Dependencies are inferred from the claim text.